- Home
- /
- Drugs
- /
- R RESPIRATORY SYSTEM
- /
- R05
- /
- R05D
- /
- R05DA
- /
- Covonia Catarrh Relief Formula / Natures Aid Herbal Catarrh Relief Formula
Covonia Catarrh Relief Formula.
Summary of product characteristics
1. Name of the medicinal product
Covonia Catarrh Relief Formula.
Natures Aid Herbal Catarrh Relief Formula
2. Qualitative and quantitative composition
Each 5ml contains:-
0.25ml of extract (as liquid extract) from Burdock root (Arctium lappa L) (1:1) (equivalent to 0.25gm Burdock root).
Extraction solvent: Water.
0.35ml of extract (as liquid extract) from Hyssop herb (Hyssopus officinalis L) (1:1) (equivalent to 0.35gm Hyssop herb).
Extraction solvent: Water.
Excipients:
Each 5ml contains 11.5vol% ethanol (alcohol)
Each 5ml contains 3.75mg dextrose (glucose).
For full list of excipients, see section 6.1.
3. Pharmaceutical form
Oral Liquid.
A brown opaque liquid.
4.1. Therapeutic indications
A traditional herbal medicinal product used to relieve the symptoms of nasal catarrh and catarrh of the throat based on traditional use only.
4.2. Posology and method of administration
For oral use only.
Adults and the Elderly: One 5ml spoonful three times a day.
The use in children and adolescents under 18 years of age is not recommended (see section 4.4 “Special warnings and precautions for use”).
Duration of use:
Do not use for more than one week.
4.3. Contraindications
Hypersensitivity to the active substances, other plants of the Asteraceae (Compositae) family or to any of the excipients.
4.4. Special warnings and precautions for use
Do not exceed the stated dose.
This medicinal product contains 11.5vol% ethanol (alcohol), i.e. up to 453 mg per dose, equivalent to 12 ml beer, 5 ml wine per dose.
Harmful for those suffering from alcoholism.
To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy.
This medicinal product contains 3.75 mg dextrose (glucose). Patients with rare glucose-galactose malabsorption should not take this medicine.
This medicinal product contains methyl and propyl hydroxybenzoates and may cause allergic reactions (possibly delayed).
The use in children and adolescents under 18 years of age is not recommended due to lack of adequate data and the alcohol content.
If symptoms worsen or persist for more than one week, a doctor or a qualified healthcare practitioner should be consulted.
If dyspnoea, fever or purulent sputum occurs, a doctor or a qualified healthcare practitioner should be consulted.
4.5. Interaction with other medicinal products and other forms of interaction
Contains alcohol and should therefore be avoided in patients taking other medication known to interact with alcohol e.g. Metronidazole.
4.6. Fertility, pregnancy and lactation
Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
Studies on fertility have not been performed.
4.7. Effects on ability to drive and use machines
No studies on the effect on the ability to drive or operate machines have been performed.
This product contains alcohol (see section 2).
4.8. Undesirable effects
Anaphylactic shock has been reported with Burdock root. The frequency is not known.
If other adverse reactions not mentioned occur, a doctor or a qualified healthcare practitioner should be consulted.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9. Overdose
No cases known.
Overdose of this product may result in alcohol intoxication. The amount of alcohol in a full bottle (9.06gm in 100ml; 13.59gm in 150ml equivalent to 0.4 and 0.6 large glasses of wine, respectively) may result in alcohol intoxication and should be treated accordingly.
5.1. Pharmacodynamic properties
Not required as per article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.
5.2. Pharmacokinetic properties
Not required as per article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.
5.3. Preclinical safety data
Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.
6.1. List of excipients
Ethanol
Caramel (E150)
Glycerol (E422)
Propyl parahydroxybenzoate
Methyl parahydroxybenzoate (E218)
Capsicum Tincture (containing capsicum oleoresin, ethanol and water)
Viscarin SD 389 (contains dextrose/carageenan (E407)
Menthol
Sodium saccharin (E954)
Purified water.
6.2. Incompatibilities
None known.
6.3. Shelf life
Three years unopened.
Once opened use within 28 days.
6.4. Special precautions for storage
Do not store above 25 °C.
6.5. Nature and contents of container
100ml amber glass sirop bottle with 28mm polypropylene white tamper-evident cap with EPE/Aluminium/Melinex liner.
150ml amber glass bottle with a 28mm polypropylene white tamper evident cap with EPE/Aluminium/Melinex liner.
150ml amber glass bottle embossed “Covonia” with a 28mm polypropylene white tamper evident cap with EPE/Aluminium/Melinex liner.
Not all packs may be marketed.
6.6. Special precautions for disposal and other handling
There are no special precautions for disposal.
7. Marketing authorisation holder
Thornton & Ross Ltd
Linthwaite, Huddersfield
West Yorkshire
HD7 5QH
United Kingdom
8. Marketing authorisation number(s)
THR 00240/0370
9. Date of first authorisation/renewal of the authorisation
21/03/2013
10. Date of revision of the text
25/07/2017
4.1 Therapeutic indications
A traditional herbal medicinal product used to relieve the symptoms of nasal catarrh and catarrh of the throat based on traditional use only.
4.2 Posology and method of administration
For oral use only.
Adults and the Elderly: One 5ml spoonful three times a day.
The use in children and adolescents under 18 years of age is not recommended (see section 4.4 “Special warnings and precautions for use”).
Duration of use:
Do not use for more than one week.
4.3 Contraindications
Hypersensitivity to the active substances, other plants of the Asteraceae (Compositae) family or to any of the excipients.
4.4 Special warnings and precautions for use
Do not exceed the stated dose.
This medicinal product contains 11.5vol% ethanol (alcohol), i.e. up to 453 mg per dose, equivalent to 12 ml beer, 5 ml wine per dose.
Harmful for those suffering from alcoholism.
To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy.
This medicinal product contains 3.75 mg dextrose (glucose). Patients with rare glucose-galactose malabsorption should not take this medicine.
This medicinal product contains methyl and propyl hydroxybenzoates and may cause allergic reactions (possibly delayed).
The use in children and adolescents under 18 years of age is not recommended due to lack of adequate data and the alcohol content.
If symptoms worsen or persist for more than one week, a doctor or a qualified healthcare practitioner should be consulted.
If dyspnoea, fever or purulent sputum occurs, a doctor or a qualified healthcare practitioner should be consulted.
4.5 Interaction with other medicinal products and other forms of interaction
Contains alcohol and should therefore be avoided in patients taking other medication known to interact with alcohol e.g. Metronidazole.
4.6 Fertility, pregnancy and lactation
Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
Studies on fertility have not been performed.
4.7 Effects on ability to drive and use machines
No studies on the effect on the ability to drive or operate machines have been performed.
This product contains alcohol (see section 2).
4.8 Undesirable effects
Anaphylactic shock has been reported with Burdock root. The frequency is not known.
If other adverse reactions not mentioned occur, a doctor or a qualified healthcare practitioner should be consulted.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
Disclaimer
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drug Licencing
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).